KCM
Kynam Capital Management Portfolio holdings
AUM
$929M
This Quarter Return
+19.13%
1 Year Return
-7.66%
3 Year Return
+163.82%
5 Year Return
–
10 Year Return
–
AUM
$1.29B
AUM Growth
+$1.29B
(+35%)
Cap. Flow
+$188M
Cap. Flow
% of AUM
14.56%
Top 10 Holdings %
Top 10 Hldgs %
82.4%
Holding
28
New
2
Increased
17
Reduced
4
Closed
–
Top Buys
| 1 |
CG Oncology
CGON
|
$64.8M |
| 2 |
Vaxcyte
PCVX
|
$32.7M |
| 3 |
Beam Therapeutics
BEAM
|
$31.9M |
| 4 |
Viridian Therapeutics
VRDN
|
$17.3M |
| 5 |
Dynavax Technologies
DVAX
|
$13.9M |
Top Sells
| 1 |
Protagonist Therapeutics
PTGX
|
$15.5M |
| 2 |
Travere Therapeutics
TVTX
|
$9.1M |
| 3 |
Tyra Biosciences
TYRA
|
$2.32M |
| 4 |
Cogent Biosciences
COGT
|
$223K |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Natera
NTRA
$23.1B
| $259M | 19.88% | 2,042,471 +28,063 | +1% | +$3.56M |
|
|
2
Vaxcyte
PCVX
$4B
| $119M | 9.1% | 1,039,288 +286,048 | +38% | +$32.7M |
|
3
Celldex Therapeutics
CLDX
$1.47B
| $118M | 9.01% | 3,458,609 +69,642 | +2% | +$2.37M |
|
4
Syndax Pharmaceuticals
SNDX
$1.41B
| $112M | 8.62% | 5,842,925 +120,868 | +2% | +$2.33M |
|
|
5
Cogent Biosciences
COGT
$1.69B
| $99.8M | 7.65% | 9,239,731 -20,654 | -0.2% | -$223K |
|
|
6
Dynavax Technologies
DVAX
$1.19B
| $92.8M | 7.12% | 8,332,687 +1,250,125 | +18% | +$13.9M |
|
7
Vera Therapeutics
VERA
$1.38B
| $69.7M | 5.34% | 1,576,549 +32,880 | +2% | +$1.45M |
|
8
BioCryst Pharmaceuticals
BCRX
$1.74B
| $69M | 5.29% | 9,085,368 +258,658 | +3% | +$1.97M |
|
|
9
CG Oncology
CGON
$2.04B
| $66.8M | 5.12% | 1,770,805 +1,716,894 | +3,185% | +$64.8M |
|
|
10
Viridian Therapeutics
VRDN
$1.5B
| $57.1M | 4.38% | 2,511,295 +761,295 | +44% | +$17.3M |
|
11
Wave Life Sciences
WVE
$1.53B
| $40.2M | 3.08% | 4,899,497 +923,976 | +23% | +$7.58M |
|
|
12
Beam Therapeutics
BEAM
$1.66B
| $31.9M | 2.45% | +1,302,085 | New | +$31.9M |
|
|
TSVT
13
DELISTED
2seventy bio
TSVT
| $28.1M | 2.15% | 5,953,825 | – | – |
|
14
Liquidia Corp
LQDA
$2.38B
| $22.7M | 1.74% | 2,266,328 +1,349,754 | +147% | +$13.5M |
|
|
15
Protagonist Therapeutics
PTGX
$3.67B
| $20.5M | 1.57% | 456,369 -343,631 | -43% | -$15.5M |
|
|
16
Travere Therapeutics
TVTX
$1.56B
| $19.2M | 1.47% | 1,371,511 -650,148 | -32% | -$9.1M |
|
17
Ironwood Pharmaceuticals
IRWD
$214M
| $15.2M | 1.16% | 3,685,563 +2,043,672 | +124% | +$8.42M |
|
18
enGene Holdings
ENGN
$236M
| $11.5M | 0.88% | +1,736,227 | New | +$11.5M |
|
|
19
Tyra Biosciences
TYRA
$675M
| $11M | 0.84% | 467,947 -98,768 | -17% | -$2.32M |
|
|
AMRN
20
Amarin Corp
AMRN
$311M
| $7.78M | 0.6% | 12,414,628 +258,798 | +2% | +$162K |
|
21
Sutro Biopharma
STRO
$72.7M
| $7.15M | 0.55% | 2,066,447 +42,764 | +2% | +$148K |
|
22
Caribou Biosciences
CRBU
$174M
| $4.62M | 0.35% | 2,356,147 +709,445 | +43% | +$1.39M |
|
|
SLRN
23
DELISTED
ACELYRIN
SLRN
| $4.18M | 0.32% | 847,366 +16,056 | +2% | +$79.2K |
|
|
BNR
24
Burning Rock Biotech
BNR
$93.6M
| $3.23M | 0.25% | 989,217 +14,549 | +1% | +$47.5K |
|
25
Alnylam Pharmaceuticals
ALNY
$58.5B
| – | – | 0 | – | – |
|